Alvogen’s Lotus Picks Up Darbepoetin Alfa Rights In Asia
Biosimilar Agreement Covers Taiwan And Key Asian Markets
Executive Summary
Lotus Pharmaceuticals has expanded its biosimilar pipeline to five by bringing in rights in Taiwan and South East Asia markets to Chong Kun Dang Pharmaceutical’s biosimilar of Kyowa Kirin’s Nesp (darbepoetin alfa).
You may also be interested in...
Deal Watch: Bausch Health Takes Option To Allegro Dry AMD Candidate
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Alvogen's Lotus Secures Deal With Fuji To Bolster Asia Presence
Alvogen’s Taiwanese subsidiary Lotus has confirmed a cross-investment partnership with Fuji that will strengthen the firms’ commercial platform in Japan and other key Asian pharmaceutical markets.
Pegfilgrastim Next As Fresenius Kabi Eyes Five Biosimilars In 2025
Fresenius Kabi has drawn up a roadmap to offering five biosimilar products by 2025, with a biosimilar to Amgen’s Neulasta (pegfilgrastim) set to rival competitors in the US and Europe later this year, ahead of a biosimilar to Roche and Chugai’s Actemra/Ro-Actemra (tocilizumab).
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: